The U.S. Food and Drug Administration announced it has approved Linzess capsules for pediatric patients 7 years and older with irritable bowel syndrome with constipation. Linzess is the first treatment approved for IBS-C in pediatric patients, the FDA noted.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRWD: